Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462690 | 0.92 | GRIN2B (0.51) | GRIN2BABCB1NPC1RAB9AHPGD | |
| SCHEMBL5468853 | 0.88 | GRIN2B (0.53) | GRIN2BMEN1KMT2A | |
| SCHEMBL5464013 | 0.82 | PDE10A (0.41) | GRIN2BABCB1PDE10A | |
| SCHEMBL5454953 | 0.81 | ALDH1A1 (0.48) | GRIN2BABCB1FFAR4 | |
| SCHEMBL5455175 | 0.79 | ABCB1 (0.42) | ABCB1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL5702162 | 0.79 | PDE10A (0.40) | ABCB1PDE10AFFAR4MEN1KMT2A | |
| SCHEMBL5462772 | 0.78 | CCR5 (0.45) | ABCB1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL5457610 | 0.77 | GRIN2B (0.37) | GRIN2BABCB1MEN1KMT2A | |
| SCHEMBL5468882 | 0.77 | GRIN2B (0.37) | GRIN2BKMT2A | |
| SCHEMBL5457386 | 0.75 | PDE5A (0.40) | GRIN2BABCB1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | PFIZER, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | GRIN1, GRIN3A, GRIN2C | GRIN2B 7/4885ABCB1 803/4885NPC1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.